🔎 Trials Near Me

홈 › 다발성 골수종 › 테네시 › Nashville

TN Nashville의 다발성 골수종 임상 시험

다발성 골수종 관련 연구 32개가 Nashville 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.

공식 연구 텍스트(영어)

연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

피험자 모집 중3상
  • Research Site, Nashville
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07391657

A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

피험자 모집 중3상
  • Tennessee Oncology, PLLC, Nashville
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07518186

A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)

피험자 모집 중1상
  • Research Site, Nashville
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07073547

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

피험자 모집 중3상
  • SCRI Oncology Partners, Nashville
  • Vanderbilt University Medical Center, Nashville
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07258511

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

피험자 모집 중3상
  • Henry-Joyce Cancer Clinic, Nashville
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05552222

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

피험자 모집 중4상
  • Sarah Cannon Research Institute, Nashville
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05201781

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

피험자 모집 중1/2상
  • Sarah Cannon Research Institute, Nashville
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT07116616

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

피험자 모집 중2/3상
  • SCRI Oncology Partners /ID# 278353, Nashville
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07095452

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

피험자 모집 중2상
  • Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville
12세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT02693535

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

피험자 모집 중2상
  • Tennessee Oncology, Nashville
  • Vanderbilt University Medical Center, Nashville
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT06297226

A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma

피험자 모집 중2상
  • SCRI Oncology Partners, Nashville
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07637578

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

피험자 모집 중1상
  • Tennessee Oncology, Nashville
18세 이상 · 모든 성별 · 2026. 8. 28. 업데이트됨 · NCT06375044

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

피험자 모집 중1/2상
  • Research Site, Nashville
18세 이상 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT07681596

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

피험자 모집 중2상
  • GSK Investigational Site, Nashville
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT07227311

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

피험자 모집 중3상
  • Ascension St. Thomas Hospital, Nashville
  • Tennessee Oncology, PLLC - Investigational Drug Services, Nashville
  • Tennessee Oncology, PLLC - Nashville Elliston Place Plaza Center for Blood Cancers, Nashville
  • 외 2개
18세 이상 · 모든 성별 · 2026. 8. 24. 업데이트됨 · NCT06152575

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

피험자 모집 중1/2상
  • GSK Investigational Site, Nashville
18세 이상 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT05714839

Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing

피험자 모집 중2상
  • Vanderbilt University Medical Center, Nashville
18세 ~ 70세 · 모든 성별 · 2026. 8. 19. 업데이트됨 · NCT07485647

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

피험자 모집 중1/2상
  • SCRI Oncology Partners, Nashville
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT06292780

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

피험자 모집 중1상
  • Tennessee Oncology, Nashville
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

피험자 모집 중1/2상
  • Research Site, Nashville
  • Research Site, Nashville
18세 이상 · 모든 성별 · 2026. 8. 17. 업데이트됨 · NCT05850234

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

피험자 모집 중3상
  • Research Site, Nashville
  • Research Site, Nashville
18세 이상 · 모든 성별 · 2026. 8. 14. 업데이트됨 · NCT07764978

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

피험자 모집 중2상
  • Tennessee Oncology, Nashville
18세 이상 · 모든 성별 · 2026. 8. 6. 업데이트됨 · NCT07284758

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

피험자 모집 중1상
  • Tennessee Oncology, Nashville
18세 이상 · 모든 성별 · 2026. 7. 16. 업데이트됨 · NCT06121843

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

피험자 모집 중1상
  • Vanderbilt Ingram Cancer Center /ID# 252470, Nashville
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT05650632

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

피험자 모집 중3상
  • Vanderbilt-Ingram Cancer Center (VICC), Nashville
18세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT05243797

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

피험자 모집 중2상
  • SCRI Oncology Partners, Nashville
19세 이상 · 모든 성별 · 2026. 6. 4. 업데이트됨 · NCT06974786

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

피험자 모집 중2상
  • TriStar Bone Marrow Transplant, Nashville
  • Vanderbilt- Ingram Cancer Center, Nashville
18세 이상 · 모든 성별 · 2026. 4. 22. 업데이트됨 · NCT05972135

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

피험자 모집 중1/2상
  • TriStar Centennial Medical Center, Nashville
12세 이상 · 모든 성별 · 2026. 3. 24. 업데이트됨 · NCT04988555

A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

피험자 모집 중1상
  • Local Institution - 0008, Nashville
  • Tennessee Oncology, Nashville
18세 이상 · 모든 성별 · 2026. 3. 18. 업데이트됨 · NCT06153251

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

피험자 모집 중관찰 연구건강한 지원자 환영
  • Vanderbilt-Ingram Cancer Center, Nashville
40세 이상 · 모든 성별 · 2026. 1. 20. 업데이트됨 · NCT05366881

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

피험자 모집 중1상
  • Tennessee Oncology, Nashville
18세 이상 · 모든 성별 · 2025. 9. 25. 업데이트됨 · NCT05722418

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

피험자 모집 중1/2상
  • SCRI Oncology Partners, Nashville
18세 이상 · 모든 성별 · 2025. 6. 3. 업데이트됨 · NCT06119685

다른 도시의 다발성 골수종 시험

Nashville의 다른 연구

ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.